Skip to Main Content
Table 2—

Adverse events recorded during the 4-week treatment period with NVP DPP728 at 100 mg t.i.d. or 150 mg b.i.d. or with placebo in subjects with type 2 diabeteslegend

NVP DPP728
Placebo (N = 32)
100 mg t.i.d. (n = 30)150 mg b.i.d. (n = 31)Total active (n = 61)
Pruritus 
Diarrhea 
Nasopharyngitis 
Hypoglycemia 
Dizziness 
Headache 
Vertigo 
Nausea 
Depression 
Urinary frequency 
Night sweats 
Constipation 
Hiatal hernia 
Weakness 
Stye 
Decreased appetite 
Myalgia 
Hypertonia 
Paresthesia 
Nephrotic syndrome 
Hoarseness 
Allergic rhinitis 
Increased sweating 
Tremor 
NVP DPP728
Placebo (N = 32)
100 mg t.i.d. (n = 30)150 mg b.i.d. (n = 31)Total active (n = 61)
Pruritus 
Diarrhea 
Nasopharyngitis 
Hypoglycemia 
Dizziness 
Headache 
Vertigo 
Nausea 
Depression 
Urinary frequency 
Night sweats 
Constipation 
Hiatal hernia 
Weakness 
Stye 
Decreased appetite 
Myalgia 
Hypertonia 
Paresthesia 
Nephrotic syndrome 
Hoarseness 
Allergic rhinitis 
Increased sweating 
Tremor 
legend

Data are n. All events recorded in the active treatment groups are shown. Eight further adverse events occurring only in the placebo arm have been omitted.

Close Modal

or Create an Account

Close Modal
Close Modal